TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15005733
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) + one dose of BCG immunization (n=16)
Study: 15005733
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (inhaled therapy only, PPD-negative asthmatics allergic to HDM, n=5)
Study: 9722121
Drug: Single-dose piperacillin
Normalized name: Piperacillin
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose piperacillin (4 g)
Study: 9722121
Drug: Multi-dose piperacillin
Normalized name: Piperacillin
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multi-dose piperacillin (3 doses of 2 g)
Study: 9722121
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cephradine and metronidazole (3 doses)
Study: 9722121
Drug: Single-dose piperacillin
Normalized name: Piperacillin
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose piperacillin vs. multi-dose piperacillin
Study: 8057223
Drug: spray-dried powder
Normalized name: Lactose, Monohydrate, Spray-Dried Powder, NF
Approvals — FDA: no, EMA: no, PMDA: no
Description: spray-dried powder formula
Study: 2971692
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg acitretin
Study: 2971692
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg acitretin
Study: 2971692
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg acitretin
Study: 2971692
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg etretinate
Study: 2971692
Drug: All acitretin
Normalized name: Acitretin
DrugBank: Acitretin (DB00459)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All acitretin doses and etretinate
Study: 2971692
Drug: Acitretin treatment
Normalized name: Acitretin
DrugBank: Acitretin (DB00459)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acitretin treatment
Study: 2971692
Drug: 3 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 weeks after cessation of treatment
Study: 26477278
Drug: FBZ >10mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: FBZ >10mg/kg once daily for five consecutive days
Study: 26477278
Drug: moxidectin (MOX)
DrugBank: Moxidectin (DB11431)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: moxidectin (MOX) >0.4 mg/kg once
Study: 21568746
Drug: Tripterygium hypoglaucum
Normalized name: Tripterygium wilfordii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tripterygium hypoglaucum Hutch (THH) 3 tablets 3 times daily
Study: 21568746
Drug: Placebo 3
Normalized name: placebo 330 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 3 tablets 3 times daily
Study: 21568746
Drug: THH with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: THH with cetirizine hydrochloride 10 mg once daily
Study: 21568746
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with cetirizine hydrochloride 10 mg once daily
Study: 18491970
Drug: Valganciclovir (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valganciclovir (900 mg once per day for 8 weeks)
Study: 16487695
Drug: Piperacillin/tazobactam (P/T)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin/tazobactam (P/T) 4 g/500 mg every 6 h
Study: 16487695
Drug: Imipenem/cilastatin (IMP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem/cilastatin (IMP) 500 mg/500 mg every 6 h
Study: 11832093
Drug: Intraperitoneal lymphatic
Normalized name: PINPOINT Lymphatics Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal lymphatic chemotherapy with carboplatin (200 mg) and sandostatin (0.1 mg x 2)
Study: 11832093
Drug: Intraperitoneal chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal chemotherapy with carboplatin (200 mg)
Study: 1630846
Drug: Dextropropoxyphene hydrochloride
Normalized name: Dextropropoxyphene hydrochloride
DrugBank: Dextropropoxyphene (DB00647)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextropropoxyphene hydrochloride (DP) 150 mg, twice a day, in a double-blind, randomized, placebo-controlled, crossover trial.
Study: 30854880
Drug: Calcitonin gene-related
Normalized name: Calcitonin gene-related peptide
DrugBank: Calcitonin gene-related peptide (DB06379)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitonin gene-related peptide (1.5 µg/min)
Study: 21985500
Drug: Oral nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral nifedipine (10 mg tablet, orally, up to five doses)
Study: 21985500
Drug: Intravenous labetalol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous labetalol (escalating doses of 20, 40, 80, 80 and 80 mg)
Study: 2478426
Drug: Starch (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starch (50 g) pudding meal (400 ml) with water (200 ml)
Study: 2478426
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with water (200 ml)
Study: 2478426
Drug: Amylase inhibitor
Normalized name: amylase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amylase inhibitor (5 or 10 g) with water and starch
Study: 2478426
Drug: Amylase inhibitor
Normalized name: amylase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amylase inhibitor (4 g) with water and starch
Study: 2478426
Drug: Amylase inhibitor
Normalized name: amylase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amylase inhibitor (5 or 10 g)
Study: 796954
Drug: Aspirin (soluble
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (soluble form of acetylsalicylic acid)
Study: 28596023
Drug: Oligofructose-enriched inulin
Normalized name: Inulin
DrugBank: Inulin (DB00638)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oligofructose-enriched inulin (OI; 8 g/day)
Study: 28596023
Drug: Maltodextrin placebo
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltodextrin placebo (isocaloric dose)
Study: 25939604
Drug: Circulating LCN2
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Circulating LCN2 levels above the median (76.6 ng/mL)
Study: 23863583
Drug: Water group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water group - patients drank 500 mL water after dinner on the evening before endoscopy, and 350 mL water before the examination.
Study: 21954526
Drug: 0.05 mg
Normalized name: biotin 0.05 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg morphium hydrochloride (MCh)
Study: 21954526
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg morphium hydrochloride (MCh)
Study: 9316951
Drug: Patient-controlled intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled intravenous meperidine analgesia
Study: 3742833
Drug: Melatonin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (2 mg daily in 5 ml corn-oil)
Study: 19066295
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human GH (0.5 mg every day) plus standardized diet and exercise program
Study: 17166305
Drug: Unilateral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral treatment
Study: 17166305
Drug: Bilateral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral treatment
Study: 9861119
Drug: Nimodipine 10
Normalized name: nimodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine 10 ml h‐1 (group N)
Study: 7714107
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg Dex (1 mg at midnight the previous night and 0.5 mg at 0700 h on the day of the test) + 3 x 10(6) IU iv IFN‐alpha 2
Study: 7714107
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg Dex (1 mg at midnight the previous night and 0.5 mg at 0700 h on the day of the test) + 2 mL iv saline
Study: 7714107
Drug: 2 mL
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL iv saline
Study: 1259521
Drug: Phenothiazines (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenothiazines (twice daily schedule)
Study: 23415543
Drug: Levodopa (L-DOPA)
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa (L-DOPA) treatment
Study: 21812263
Drug: Astragalus Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astragalus Injection (2 mL/kg)
Study: 19442784
Drug: Doxycycline (DOX;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (DOX; 20 mg) twice a day
Study: 19442784
Drug: Levonorgestrel-releasing subcutaneous
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levonorgestrel-releasing subcutaneous implant (LNG SI)
Study: 16928840
Drug: Ethyl vinyl
Normalized name: METHYL VINYL ETHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethyl vinyl chloride vapocoolant spray
Study: 16928840
Drug: Isopropyl alcohol
Normalized name: Isopropyl Alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isopropyl alcohol spray (placebo)
Study: 11343405
Drug: Activities where
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activities where participant was the agent of action.
Study: 8186064
Drug: Oxitropium bromide
Normalized name: oxitropium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxitropium bromide (200 micrograms three times daily)
Study: 30462938
Drug: Lactobacillus rhamnosus
Normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus rhamnosus GG (1×10^10 CFU twice daily for 5 days)
Study: 23297772
Drug: Amoxicillin (AMX,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (AMX, 500 mg) + Metronidazole (MET, 250 mg), TID for 10 days
Study: 20492045
Drug: Chinese food
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese food therapy (specific dietary instructions, management of antihypertensive medication, brief health education)
Study: 20492045
Drug: Chinese food
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese food therapy
Study: 12580992
Drug: Garlic supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic supplements (10 mg of Natural Source Odourless Garlic)
Study: 10867376
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving only pharmacotherapy
Study: 10867376
Drug: D. Pteronyssinus
Normalized name: D. farinae extract 6 SQ-HDM / D. pteronyssinus extract 6 SQ-HDM Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: D. Pteronyssinus immunotherapy
Study: 10867376
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving medication only
Study: 6685418
Drug: Hormonal treatment
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal treatment for mastopathy
Study: 6685418
Drug: Non-hormonal treatment
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-hormonal treatment for mastopathy
Study: 6685418
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment of mastopathy
Study: 26768126
Drug: Subcutaneous (s.c.)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (s.c.) TBE vaccination
Study: 26768126
Drug: Intramuscular (i.m.)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (i.m.) TBE vaccination
Study: 22483860
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no PRGF treatment)
Study: 20618356
Drug: Adrenaline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline infusion (0.1 nmol kg⁻¹ min⁻¹)
Study: 15922478
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg emtricitabine once daily
Study: 15922478
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg emtricitabine once daily
Study: 15922478
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg emtricitabine once daily
Study: 15922478
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg emtricitabine open-label after 48 weeks
Study: 10370678
Drug: Intra-arterial chemotherapy
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial chemotherapy with doxorubicin 50 mg/m2
Study: 10370678
Drug: Systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy with doxorubicin 50 mg/m2
Study: 8677192
Drug: Water, Na,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water, Na, Ca, Mg, and oxalic acid excretion in patients with ARSD under water immersion (IW)
Study: 8677192
Drug: Correlation between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation between serum ANP levels and urinary excretion of Na, Ca, and Mg in patients with ARSD
Study: 8677192
Drug: Correlation between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation between serum ANP levels and urinary excretion of oxalic acid in patients with ARSD during water immersion (IW)
Study: 6626018
Drug: Topical 1%
Normalized name: fluoride topical 1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1% aqueous suspension
Study: 6626018
Drug: Topical 1%
Normalized name: fluoride topical 1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1% oil suspension
Study: 26209003
Drug: Loop diuretics
Normalized name: LOOP DIURETICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loop diuretics (40 mg furosemide equivalents)
Study: 22421631
Drug: Nebivolol (10-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol (10-40 mg/day, titrated based on BP response)
Study: 12242072
Drug: Group CTL
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group CTL (non-treatment of atrial fibrillation relapse)
Study: 24533697
Drug: Pasireotide 600/900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide 600/900 μg bid
Study: 22145743
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene educational programs
Study: 22145743
Drug: Frequency of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frequency of oral hygiene behaviour at 3 months
Study: 17551129
Drug: 1 mg/d
Normalized name: Lyllana 0.1 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/d of folic acid
Study: 15198752
Drug: Cognitive-behaviour therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behaviour therapy intervention program (6 sessions between weeks 2 and 6 after birth)
Study: 3288460
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg pirenzepine daily intravenously for a mean of 3.9 days
Study: 3288460
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg ranitidine daily intravenously for a mean of 3.9 days
Study: 3288460
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg ranitidine
Study: 30683061
Drug: Garlic extract
Normalized name: Garlic Extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic extract (400 mg twice a day for 8 weeks)
Study: 26563012
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (1 mg/kg), administered once daily for 2 days and tapered down, completed on day 10
Study: 26563012
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (1 mg/kg)
Study: 23308174
Drug: Pegfilgrastim (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegfilgrastim (100 ug/kg single dose)
Study: 23308174
Drug: Filgrastim (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filgrastim (5 ug/kg/day for 9 doses)
Study: 16440209
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine oestrogen (CEO) 0.625 mg daily
Study: 10962221
Drug: Adjunctive imipramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive imipramine added to fluphenazine decanoate and benztropine
Study: 10962221
Drug: Adjunctive antidepressant
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive antidepressant medication
Study: 1613811
Drug: GM-1 ganglioside
Normalized name: IMMUNOGLOBULIN G1, ANTI-(GANGLIOSIDE GD2) (HUMAN-MUS MUSCULUS MONOCLONAL CH14.18 HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL CH14.18 LIGHT CHAIN, DIMER
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-1 ganglioside treatment
Study: 6488704
Drug: Low tar
Normalized name: Coal Tar
DrugBank: Coal tar (DB11082)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low tar cigarette with nicotine yield of 0.55 mg (LN)
Study: 6488704
Drug: Low tar
Normalized name: Coal Tar
DrugBank: Coal tar (DB11082)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low tar cigarette with nicotine yield of 0.90 mg (MN)
Study: 24824051
Drug: Pre-treatment snack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment snack with education messages
Study: 20956409
Drug: Prenatal corticosteroid
Normalized name: Ardisia crenata root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenatal corticosteroid therapy
Study: 15329600
Drug: Dexmedetomidine (0.09,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.09, 0.24, 0.54, and 1.23 ng/ml)
Study: 15329600
Drug: Alfentanil (13.4,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil (13.4, 33.8, 67.8, and 126.1 ng/ml)
Study: 7982345
Drug: Newer pharmacologic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Newer pharmacologic agents
Study: 29603130
Drug: Inspiratory Muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory Muscle Training (IMT) - home-based program using a flow-resistive inspiratory loading device, training twice a day at high intensity for 2 weeks or longer until surgery
Study: 24899130
Drug: Composite graft
Normalized name: polyvinyl alcohol graft polyethylene glycol copolymer (3:1; 45000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Composite graft (bioactive porous Poly dl-lactide-co-glycolide scaffolds with antibiotic gentamicin and crosslinked gelatin)
Study: 22237870
Drug: Partially hydrolyzed
Normalized name: Human Skin Proteins, Partially Hydrolyzed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partially hydrolyzed whey formula with 10(6) CFU Bb12/g (PRO)
Study: 18423901
Drug: Unobserved dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unobserved dosing
Study: 18423901
Drug: Observed dosing
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Observed dosing
Study: 15746667
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol (50 microg initially followed by 100 microg in each subsequent dose)
Study: 15746667
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol (25 microg in each dose)
Study: 12933402
Drug: Phenylephrine 2
Normalized name: phenylephrine 2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine 2 micro g/kg
Study: 11103227
Drug: Tofu (290
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofu (290 g daily)
Study: 11103227
Drug: Meat (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meat (150 g lean meat daily)
Study: 8624148
Drug: Topical 0.1%
Normalized name: adapalene topical 0.1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.1% tretinoin cream
Study: 6700383
Drug: Thrice weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice weekly intra‐muscular injections of 7.5 to 10 megaunits of interferon/m2
Study: 6700383
Drug: Daily injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily injections of interferon
Study: 30394493
Drug: Negative pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative pressure wound therapy, mean duration 10.1±3.9 days
Study: 22929964
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extract (250 or 500 ml of a milk whey based green tea containing soft drink)
Study: 17563741
Drug: Intensive timed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive timed induction therapy
Study: 15649852
Drug: Inhaled salmeterol
Normalized name: salmeterol Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled salmeterol 50 microg bid
Study: 15649852
Drug: Inhaled salmeterol
Normalized name: salmeterol Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled salmeterol 100 microg bid
Study: 15649852
Drug: Theophylline (orally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (orally dose titrated slow‐release)
Study: 9951784
Drug: Calcium and
Normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium and calcitriol supplements
Study: 2696020
Drug: No supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: No supplements
Study: 3297230
Drug: Oxycone-papaverine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycone-papaverine (5 mg + 50 mg)
Study: 31689141
Drug: Telemedicine intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telemedicine intervention (TM-group) with follow-up every 3 months and monthly telemedicine support.
Study: 19058068
Drug: Ovarian cancer
Normalized name: Autologous, DNP-Modified Ovarian Cancer Vaccine
DrugBank: DNP-Modified autologous tumor vaccine (DB17436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovarian cancer psychoeducational intervention (OCPI) - 4 sequential, structured, in-person educational sessions
Study: 20562702
Drug: TAK-242 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-242 1.2 mg/kg/day